搬运 career 2
Job and Career Opportunities in the Pharmaceutical Sector
By Josse R. Thomas, Chris van Schravendijk, Lucia Smit and Luciano Saso
Submitted: March 27th 2016Reviewed: October 20th 2016Published: November 30th 2016
DOI: 10.5772/66422
Home > Books > Special Topics in Drug Discovery
Downloaded: 3580
Abstract
The pharmaceutical field offers a wealth of job and career opportunities for talented young graduates with a sound background in life sciences and various other academic disciplines. Because these employment options are often insufficiently known to young academics, the aim of this chapter is to give them a better idea about the many job opportunities and presents the entire drug life cycle. The first part of the chapter includes a general description of the drug life cycle and what is understood by ‘the pharmaceutical sector’. The core of the chapter gives an overview of job opportunities that either are specific to the different parts of the drug life cycle or are important as support functions over the entire life cycle. It also includes a section on career perspectives and training opportunities. The last part of the chapter focuses on important employability elements, as well as some practical do’s and don’ts for effective job application.
Keywords
- job
- career
- drug discovery and development
- pharmaceutical sector
Chapter and author info
Show +
1. Introduction
The field of drug discovery, development and commercialisation offers a wealth of job and career opportunities for talented young graduates with a sound background in life sciences or other academic disciplines and a genuine interest and motivation to start a professional career in the pharmaceutical sector.
The drug life cycle is usually subdivided into discovery research, development and commercialisation and spans the whole trajectory from idea to patients, from bench to market (withdrawal).
The professional field covers the whole pharmaceutical sector, which is not just limited to drugs or to medicines for human or animal use but also includes medical devices, diagnostics, radiopharmaceuticals, nutriceuticals and other related areas of activity. Nor is this sector limited to the (bio-)pharmaceutical industry, but it also includes health authorities, academia and research centres, clinical investigator sites, contract research organisations (CROs) and many more. The need for a highly educated workforce is clearly present in all of these areas and the pharma sector is offering opportunities for a wide spectrum of academic graduates with a Bachelor, a Master, or a PhD degree. Despite the many job opportunities in this sector, competencies of young university graduates are seldom adjusted to the specific requirements listed in the job vacancies. Moreover, they often lack an understanding of the drug development process and the various perspectives it offers for career development.
The aim of this chapter is to give academic graduates a better idea about the many job opportunities over the entire drug life cycle, offered by a wide variety of companies and organisations and for a broad spectrum of qualified professionals.
All the above will be presented in more detail in Sections 2–5 of this chapter.
After the overview of job opportunities, career perspectives and training opportunities will be discussed in Sections 6 and 7 and important employability elements in Section 8.
As this chapter is primarily targeted at young graduates, Section 9 adds some practical dos and don’ts for effective job application. The chapter ends with some concluding remarks (Section 10) and a bibliography for further reading.
8 seconds of 1 minute, 14 secondsVolume 0%
2. The drug life cycle
The life cycle of a drug involves essentially three parts: drug discovery and design (research), drug development and drug commercialisation [1]. They are largely consecutive in nature, but some activities are carried out in parallel.
Drug research is primarily driven by an unmet medical need, i.e. a therapeutic area in need of a (better) drug. Drugs are either discovered in nature or in existing chemical libraries, or either (semi-)synthesised or designed de novo in laboratories. Drug discovery research and drug design require highly intellectual creativity, perseverance and some serendipity. As drugs interact with molecular targets of biological relevance for a disease, mostly proteins (such as receptors, enzymes, ion channels, or antigens), drug research requires intense collaboration between project team members of several scientific disciplines (such as biologists, medicinal chemists and pharmacologists). Drug discovery and design are characterised by a fairly high degree of freedom. It is mostly done in (big) pharmaceutical companies, academic research centres, as well as in small spin-offs and start-ups. The ultimate goal of the research project team is to deliver a (few) patented drug candidate(s), ready for development. This can take 3–5years.
During drug development, the potential drug candidate progresses to a drug or a medicinal product which is effective and safe to be administered to humans (or animals) to prevent, diagnose, or treat a disease. It is a complex and highly regulated process, with a lot of intermediate failures, (re-)assessments and (re-)iterations along the long road. Because of these characteristics, drug development is often subdivided in non-clinical and clinical development, as well as in early and late development. In drug development for humans, clinical development includes all experiments with the drug in human subjects (healthy volunteers or patients), while non-clinical development includes all experiments with the drug in animals, in vitro and in silico. Non-clinical development consists of chemical and pharmaceutical development (of the drug product as a formulation, such as a tablet or an injectable solution), non-clinical efficacy and safety pharmacology, non-clinical toxicology and non-clinical pharmacokinetics. Non-clinical development is partly preclinical, i.e. some of it has to be performed and has to generate safe results before (a certain phase in) clinical development can start. Clinical development is classically divided into consecutive phases: phase 1 (first administration in man, single and multiple ascending dose studies, mostly in healthy volunteers), phase 2 (proof of concept that the drug has the intended effect in patients with the targeted disease, dose-finding studies), phase 3 (confirmation of efficacy and safety in clinical trials with large groups of patients), phase 4 (real-world studies when the drug is on the market, pharmacovigilance). Alternatively, clinical development is also split into an exploratory and a confirmatory phase, or a preapproval (before market authorisation) and a post-approval phase. Drug development is a highly risky and costly process; it takes easily 5–8years and a very talented team of several disciplines (different life scientists, clinicians, engineers, regulatory affairs experts and others), all working together to make it a successful enterprise.
The final part, drug commercialisation, starts with the market authorisation (or drug approval), based on all the available data about quality, efficacy and safety on the medicine and a positive benefit-risk balance in the targeted population, allowing the drug to be marketed and to generate return on investment. But market authorisation (per country, per region like the European Union, or worldwide) is not enough to be successful on the market; there are other hurdles to be taken such as a fair price setting and drug reimbursement by social security systems (based on the added value of the drug for patients and its affordability by society), together known as market access hurdles. Once taken, the drug can be launched and marketing and sales can really start, in parallel with large-scale production and distribution. When the patent of the drug expires (generally 20years after its application), generic and biosimilar competitors enter the market and the sales of the original drug suddenly drop (the patent cliff), but a drug with added value can still stay on the market for many more years, until it is finally withdrawn. Drug commercialisation is more a world of health economists, marketers, pharmacists, pharmaceutical physicians, sales reps, lawyers and business managers. A schematic representation of the drug life cycle is given in Figure1.
3. The pharmaceutical sector
The (bio-)pharmaceutical industry is probably the biggest employer in this sector worldwide.
It is already a world in itself, as it is an umbrella term with its main representatives being ‘big pharma’ companies, active throughout the whole value chain of the drug life cycle. They research, develop, manufacture and market innovative medicines, either the more classic small molecules or the more recently introduced large biopharmaceuticals such as therapeutic proteins and monoclonal antibodies (produced by living organisms or cells). Under the umbrella also operate medtech companies (e.g. medical devices, implants, biomaterials and in vitro diagnostics); biotech companies specialised in biopharmaceuticals, but also in advanced therapy medicinal products (ATMPs) such as gene and cell therapy, or tissue-engineered products; small- and medium-sized enterprises (SMEs) often as niche players; start- or scale-up companies more focused on drug research and early development; companies producing generics and biosimilars; organizations representing the pharmaceutical industry, such as PhRMA in the USA and EFPIA in Europe; and last but not least, the ever growing business of Contract Research Organizations (CROs) as full or specific service providers to this industry.
However, the pharmaceutical sector is a lot broader than the pharmaceutical industry and offers many additional jobs and career opportunities. Other important organisations, institutions, or actors in this sector are regulatory agencies, such as national or regional medicines agencies (such as the FDA in the USA and the EMA in Europe, granting drug approvals), certified bodies (the equivalent for medical devices), or patent offices; academia, research centres and spin-offs active in basic research, drug discovery and design, but also early drug development; clinical investigator sites, be it phase 1 or clinical pharmacology units (CPUs) either university- or CRO-owned, university or regional hospitals, site management organisations (SMOs), or the European Organisation for the Research and Treatment of Cancer (EORTC); patient organisations; non-profit drug research funders such as the Bill and Melinda Gates Foundation; consultants, lobbyists and law firms; venture capitalists and investment banks; entrepreneurs and self-employed persons; and many more…
Overall, the pharmaceutical sector offers a wealth of job opportunities and career perspectives for young and talented graduates of the necessary calibre and commitment.
4. Job opportunities throughout the drug life cycle
In this section, we walk through the drug life cycle and focus on job opportunities that are specific to the different parts of the cycle. Support functions that are important over the entire cycle are presented in Section 5.
4.1. Discovery research
Drug discovery research is either phenotypic-based (empirical and response-driven) or target-based (molecular and hypothesis-driven). Although the phenotypic-based approach has been very successful in the past, today’s drug discovery is more target-based. The process is as follows: (1) selection and validation of a (druggable) target, mostly a protein (e.g. receptor, enzyme, ion-channel and antigen), but also carriers of genetic information (e.g. DNA/RNA and oncogenes); (2) development and validation of a proper assay, allowing to study the interaction between the target and potential drug candidates; (3) (high-throughput) screening (HTS) of potential drugs, generated through de novo synthesis or from existing natural or chemical libraries, in order to identify ‘hits’ (interactions with the target); (4) hit-to-lead finding, i.e. limited optimisation of drug candidates in order to identify a limited number of promising lead compounds; (5) lead optimisation, with the objective to improve target selectivity and specificity, as well as the pharmacodynamic, pharmacokinetic and toxicological properties of the candidate drug, in order to get it ready for development.
Drug discovery research is highly dependent on the interplay between different scientific and other disciplines. In practice, it includes intensive collaboration between mainly:
- different types of biologists, such as molecular biologists, biochemists, biotechnologists, bioinformaticians and biomedical scientists;
- different types of chemists, such as medicinal chemists, combichem specialists, computer-assisted drug designers, protein chemists and analytical chemists;
- pharmacologists, pharmacokineticists, pharmacometricians, toxicologists, biopharmacy and pharmaceutical technology experts;
- as well as representatives of other disciplines, such as (bio-)engineers, data analysts, intellectual property (IP) specialists and patent lawyers.
Drug research departments may be organised per therapeutic domain (more specialised and more compartmentalised) or rather more ‘holistically’ per biological platform, such as a similar target family (e.g. kinases and ion channels), or a similar biological mechanism (e.g. angiogenesis, inflammation, cell cycle control and epigenetics), or per common technological platform (e.g. 3D modelling, X-ray crystallography and NMR spectroscopy).
Innovative drug research organisations (pharmaceutical companies, academic centres, spin-offs, or start-ups) are looking for highly educated and talented individuals with at least a master’s degree and preferably a PhD in the aforementioned disciplines. However, being an excellent scientist is not enough to be successful in this field. You also need the right creative mindset, being able to think out of the box and to work together in a multidisciplinary team on a specific project for several years.
Discovery research is the least regulated phase of the drug life cycle and confers to professionals working in this field a fairly high degree of freedom, although in the competitive world of today, research teams also have to deliver quality products, in time and within budget.
As drug R&D is costly and risky; drug candidates are patented so that they later gain market exclusivity without competition for a set period (in general, 20years after patent filing). Therefore, drug research organisations as well as national and international patent offices also offer job opportunities for IP specialists, such as patent lawyers and patent reviewers.
4.2. Non-clinical development
Non-clinical drug development, including all experiments not involving human subjects, is an umbrella term referring to the following activities: chemical and pharmaceutical development (also known as ‘chempharm’ or ‘chemistry, manufacturing and controls (CMC)’), experimental pharmacology (including safety pharmacology), non-clinical toxicology and non-clinical pharmacokinetics. It is essentially a lab activity, involving in vitro and in silico research as well as animal experiments. Its goal is to generate the data needed as prerequisites for the different clinical development phases (the preclinical part of non-clinical development), all the non-clinical data for the marketing authorisation application (the preapproval phase), as well as all the non-clinical data during the continued development when the drug is already on the market (the post-approval phase). Non-clinical development is much more regulated than discovery research and has to be executed within a framework of international guidelines (ICH Quality and Safety guidelines) and according to the international standards of good laboratory or good manufacturing practices (GLP and GMP).
Chemical and pharmaceutical development, including drug (product) manufacturing and drug (product) analysis, offers opportunities especially for analytical and green chemists, chemical or bio-engineers, pharmaceutical technologists and (industrial) pharmacists.
Non-clinical efficacy and safety pharmacology units are rather looking for experimental pharmacologists, biomedical, or (bio-)pharmaceutical scientists.
Non-clinical pharmaceutical toxicology departments are essentially in need of toxicologists, veterinary surgeons and pathologists, but can also do well with interested biomedical or (bio-)pharmaceutical scientists.
Non-clinical pharmacokinetics departments are especially looking for pharmacokineticists, experts in drug metabolism and bio-analytical chemists. As model-based drug development is booming, there is also a high need for pharmacometricians, modelling and simulation experts, or more generally, biomedical or (bio-)pharmaceutical scientists with a sound background in mathematics.
For most executive functions in all the above-cited fields, having a master’s degree is an absolute must and a PhD a big plus, although a lot of lab technicians are also welcome.
Non-clinical drug development specialists are also needed in (inter-)national medicines agencies as assessors of the CMC (quality) and the non-clinical (safety) parts of the common technical document (CTD), the international harmonised dossier for application of a marketing authorisation of pharmaceuticals for human and animal use.
4.3. Clinical development
Clinical drug development, defined as all studies involving human subjects, is (because of its complexity and long duration) usually subdivided into different phases. It starts classically with small-scale phase 1 studies, including the First-in-Man or First-in-Human (FiM/FiH) study, the single ascending dose (SAD) and the multiple ascending dose (MAD) studies, usually in healthy volunteers (but sometimes in patients), in order to have a first impression of the safety, pharmacokinetics and pharmacodynamics of the drug in development in humans. Then follows phase 2a, to investigate whether the drug works at all in patients according to the presumed mechanism of action (the so-called Proof-of-Concept or POC study) and to have a preliminary idea about the effective and safe dose range in tens of patients with the intended indication. Nowadays, phase 1 is often preceded by a phase 0 study with a limited number of subjects, with a single radioactive microdose of a limited number of drug candidates in order to help researchers in the selection of the best candidate for further full development. In a more recent classification, the preceding phases are together defined as ‘early’ or ‘exploratory’ clinical drug development. The corresponding ‘late’ or ‘confirmatory’ clinical development phase is then corresponding to the classic phases 2b, 3 and 4. The main objective of phase 2b is proper dose (regimen) finding in hundreds of patients with the targeted disease, whereas phase 3 clinical trials aim at confirming a positive clinical benefit/risk balance versus existing therapies in thousands of patients. If successful after this phase, a marketing authorisation application is filed, allowing the drug, if granted, to be put on the market and generate return on investment. This part of the late development phase is also called the preauthorisation or preapproval phase. Finally, in phase 4 of clinical drug development (the post-authorisation or post-approval phase), the use of the drug in everyday clinical practice is studied, its pharmacovigilance (adverse drug reactions) is (are) monitored and new developments are initiated (for new indications, new associations, or new formulations).
Clinical drug development also involves many different disciplines, each offering several job opportunities. Within clinical drug development organisations (e.g. pharmaceutical companies and CROs), they are usually grouped in the following departments: Clinical Research, Clinical Operations, Medical Review and Pharmacovigilance, Clinical Biometry and Clinical Services, although names can vary from company to company. Their role is to extensively collaborate with one another and generate all clinical data for the marketing authorisation application (preapproval phase), as well as all clinical data for continued developments in the post-approval phase.
Clinical Research is responsible for the content of the clinical development plan of the new drug. They define the strategy, do the planning, oversee the methodology and coordinate the overall (worldwide) management of all clinical trials. In the early clinical development phase, they primarily need clinical pharmacologists, clinical pharmacokineticists, clinical pharmacometricians, but also clinicians (either medical specialists or general practitioners). In the late clinical development phase, this need shifts more towards clinicians and pharmaceutical physicians, pharmaco-epidemiologists and (hospital or clinical) pharmacists.
Clinical Operations is in charge of the implementation of the clinical development plan, the local project management, as well as the monitoring and administration of all clinical trials. They typically hire international and local clinical trial managers, clinical research associates (CRAs or monitors) and clinical trial administrators (CTAs), often with just a master’s degree in life sciences (e.g. biomedical or pharmaceutical scientists, research nurses, physiotherapists, or even physicians).
The Medical Review and Pharmacovigilance Department is populated by medical reviewers and pharmacovigilance (PV) experts, responsible for the critical review of all medical data gathered in clinical trials and especially all data on adverse events and adverse drug reactions. These aspects are best handled by (pharmaceutical) physicians (hospital or clinical) pharmacists and clinical toxicologists, with the external help of clinicians and medical specialists for specific problems.
The Clinical Biometry unit, in charge of clinical data management and clinical statistics, is particularly looking for clinical trial methodologists, data managers, (big) data analysts, biostatisticians and computer programmers.
And finally, the Clinical Services Department is responsible for the supply and logistics of all clinical study material, e.g. supply, storage and shipment of investigational drugs (including placebo and comparators) and central laboratory materials (to and fro the study centres, all over the world), or provision of standardised study equipment (e.g. a treadmill for exercise tolerance tests, including the software to run the test). They usually hire pharmaceutical or biomedical scientists for these jobs.
Clinical drug development specialists are also needed in (inter-)national medicines agencies as assessors of the clinical parts of clinical trial or investigational new drug applications (CTA in Europe, IND in USA) and Marketing Authorisation (MA, Europe) or New Drug Applications (NDA, USA).
A particular characteristic of clinical drug development is that clinical trials are largely performed in investigational sites that do not belong to the drug development organisation itself. With the notable exception of phase 1 trials, usually performed in phase 1 units with healthy volunteers (of which some are owned by pharmaceutical companies or CROs), clinical trials recruit patients who can only be found in institutions, e.g. (university) hospitals, academic phase 1 units, or nursing homes, or else in private practices of general practitioners or medical specialists. Besides, many (academic) hospitals perform their own clinical (drug) research as investigator-initiated trials (IIT). All these investigational sites also offer a lot of job opportunities as investigator, research physician, research nurse, study coordinator and clinical research pharmacist. Some sites are grouped in site management organizations (SMO) or specific organizations such as the European Organisation for Research and Treatment of Cancer (EORTC) that coordinate clinical trials for their member sites. They too need qualified professionals.
4.4. Commercialisation
The last part of the drug life cycle and hopefully the longest for many years, is the commercialisation phase. It starts with the marketing authorisation of the new medicine and ends with its withdrawal from the market, thus also ending its life cycle (see Figure1). During this phase, there is a period that an innovative drug can be on the market without competition thanks to its patent protection and additional exclusivity rights, so that the owner can maximise its return of investment (ROI). Once off-patent, sales in general suddenly drop (the patent cliff) because of the introduction of generics or biosimilars, but may find a new equilibrium for years thereafter.
Drug commercialisation activities are mostly the prerogative of pharmaceutical companies, although some can also be subcontracted to CROs. They can be found in the following departments: market access, marketing, medical affairs, production and distribution and sales.
A marketing authorisation is not sufficient to get a drug for human use on the market. You also need to negotiate a fair price with different national health authorities (price setting) and to demonstrate added value in order to gain acceptable coverage or reimbursement conditions with different national health insurance system providers. These steps are known as market access hurdles. Market access departments mainly group financial experts, drug pricing specialist, experts in health technology assessment (HTA), pharmaco-economists, core value dossier writers and pharmaceutical policy experts, together with marketing specialists. They generally hire professionals with specific qualifications such as Master of Finance or Economics, but also life scientists (pharmacists, physicians and biomedical scientists) often with a second degree in, for instance, health economics or pharmaceutical medicine. Similar jobs can, of course, also be found in the national institutes, agencies, or committees that have to decide on drug prices and reimbursement conditions.
Pharmaceutical marketing is responsible for promoting the sales of a (new) medicine. It supposes a good knowledge of the pharmaceutical market, general marketing principles (communicating the value of a product to customers), specific pharmaceutical marketing principles (e.g. operating in a regulated market), as well as the specificities of pharmaceutical marketing activities (market analysis, marketing strategy and plan, marketing channels and tools) adapted to the different phases of the commercial life span of a drug (prelaunch, launch, ascending phase, maturity and end-stage phase); and all this, within the rules of local drug promotion, legislation and regulation. This is typically the work space of national or international product managers and brand or group product managers (responsible for several drugs within a given therapeutic area), either specialists with a marketing degree or life scientists with a Master in Business Administration (MBA).
Medical affairs focuses on clinical drug development in the post-approval phase and on the medical and scientific aspects of pharmaceutical marketing, such as managing medical communications and publications, key opinion leaders (KOLs) and advisory boards and medical information (answering questions from health care providers and patients). Medical affairs professionals bridge the gap between R&D and marketing and hold positions such as medical advisor, medical science liaison (MSL), medical information manager, or pharmacovigilance expert, usually filled by physicians or pharmacists, often with a postgraduate degree in pharmaceutical medicine.
Pharmaceutical sales is the ultimate activity that brings in the money to reinvest in new drug R&D. The sales teams are made up of pharmaceutical sales representatives or (medical) reps, who promote (a selection of) the drugs of a pharmaceutical company. Prescription drugs are promoted toward physicians, while non-prescription drugs (over-the-counter or OTC medication) is promoted toward pharmacists. Sales reps are usually responsible for a given franchise or therapeutic class of drugs, a given target audience (private practices or hospitals) and a given local territory. There work is supervised by regional and country sales managers. Most pharmaceutical companies have their own sales force, but additional sales reps can either be (temporarily) insourced from a CRO, or the entire sales activity for a given franchise or brand can be outsourced to a CRO. Sales departments typically hire holders of bachelors and masters in life sciences (including physiotherapists), with strong communication skills and the necessary motivation and stamina to reach sales objectives, which are trained in-house and on the job.
Finally, pharmaceutical production facilities make sure that the necessary volumes of medicines are manufactured in due time with high quality, from the active pharmaceutical ingredient (API) to the end product. The distribution department sees to it that drug orders are channelled appropriately in order to reach wholesalers, community and hospital pharmacies on a regular basis. This is typically a world of chemical engineers, industrial pharmacists and supply chain managers.
5. Job opportunities in support and management functions
Within drug development organisations (e.g. mostly pharmaceutical companies, CROs or specialised start-ups and more rarely academic research centres or spin-offs), all the disciplines described above have to work together with the additional help of data managers, data analysts, (bio-)statisticians, quality management experts, specialists in regulatory sciences/affairs, report writers and planning specialists. The coordination and oversight are kept by project team leaders (who prepare the documents needed for decision-making), while go/no go-decisions are taken by (a team of) senior managers.
These activities in the pharma sector are not only important in a specific part of the drug life cycle, but cover the entire business and value chain. They too offer many job opportunities.
5.1. Regulatory sciences/affairs
As the pharmaceutical sector is highly regulated, the regulatory affairs department makes sure that their pharmaceutical organisation or company complies with all (inter-)national legislations, regulations and guidelines pertaining to their business (worldwide). They are at the forefront in the negotiations with medicines agencies when asking them for scientific advice, or when discussing with them about the marketing authorisation of a new drug, or when arguing about changes to the Summary of Product Characteristics of a drug (SmPC in Europe, labelling in USA). They also see to it that all regulatory documents, such as clinical trial applications, marketing authorisation applications and variations, as well as drug safety reports are prepared, assembled and send to the appropriate health authorities in due time. Regulatory affairs professionals may be responsible for a country or a geographical region (e.g. Europe, USA, or Asia), or they may be specialised in preapproval or post-approval affairs. Most of them are pharmacists or occasionally other life scientists, often with a post-graduate in regulatory sciences or pharmaceutical medicine.
5.2. Quality management
The quality of all the activities at all the steps and levels throughout the drug life cycle is assured by a quality management system (QMS) that typically consists of a set of rules and regulations (good practices or GxP), translated into standard operational procedures (SOP), the proper application of which is regularly monitored by quality control during operations (by self-control and monitoring) and occasionally checked by audits (by internal or external auditors) and inspections (by regulatory authorities).
Quality management professionals oversee that all operational departments comply with the recommended best practices, e.g. good laboratory practices (GLP), good clinical practices (GCP), good manufacturing practices (GMP), good pharmacovigilance practices (GVP), good distribution practices (GDP). Typical quality assurance (QA) activities include SOP writing, training of operational staff and investigator teams in quality management and performing audits from which lessons can be learned for further improvement of activities or processes.
QA professionals are usually life scientists, often with a postgraduate degree in quality management and with previous experience in an operational function in the pharmaceutical sector. Inspectors from health authorities are usually pharmacists.
5.3. Scientific/medical writing
All the activities throughout the drug life cycle generate a lot of study reports, publications, regulatory documents and applications to be written in several languages. Most pharma companies have a scientific and/or medical writing department responsible for that. These departments are populated by life scientists and translators with excellent writing and communication skills. Some of these professionals are self-employed and work as external service providers on a freelance basis.
5.4. Training and development (personal, professional)
Most pharmaceutical companies have their proper training department or corporate training academy, but there is also a plethora of training opportunities offered by specialised service providers (either in-house or external). Their objective is to provide the induction training to newcomers (including company-specific strategic thinking and knowledge transfer), as well as continuous training and development for all (individuals and teams). Training activities are offered to all operational disciplines throughout the drug life cycle, e.g. to researchers, clinical research associates, project and product managers and sales reps. These learning activities are not only meant to optimise their technical knowledge, but also target as much at the development of their core workplace skills. Trainers come in all shapes and sizes, have different backgrounds and qualifications, should have some expertise in the field to be taught, but most of all should have excellent communication and teaching abilities and should love to work with people. The rest can be learned on the job by training the trainer.
5.5. Management
The success of any business depends heavily on the effectiveness of its managers. This is equally true in the complex pharmaceutical sector, where many aspects of management come into play, such as strategic management (e.g. innovation, portfolio or risk management and go/no go decision-making) as well as operational management (e.g. project management, clinical, or sales operations). Therefore, there is a high need for visionary leaders and talented managers in this sector. Some people have inborn leadership and management talents, but others grow in it during their career development. Senior and corporate managers in the pharmaceutical business have different backgrounds and qualifications, from life scientists to economists and lawyers, often with a Master in Business Administration (MBA).
6. Career perspectives
At entry, young professionals are often employed as a junior or an assistant, preceding their functional job title (e.g. Junior or Assistant Project Manager). After a year or two, these prefixes can be dropped and after an additional number of years of experience in the same job the prefix can change to Senior (e.g. Senior Project Manager).
Initial on-the-job training and work experience can be gained during traineeships, internships, job or work shadowing, secondments and temp jobs (all paid or not).
In the (bio-)pharmaceutical industry, many young academics start their career as an employee of a CRO, which then outsources them for a certain period (6months or a year) to a pharmaceutical company for a specific job. After a couple of such secondments in different companies, these young professionals get a better idea of what they really want and what is offered out there for their future career development.
After an initial work experience of a varying number of years, young professionals usually start thinking of their career development in the pharmaceutical sector. An important element to consider is whether you want to stay an expert in your field or become a manager or a leader, as they require different skills, training and work experience.
Career moves can be of several types:
- You can move along the path of the drug life cycle, e.g. you can start in Clinical Operations (as Project Manager) and move to Regulatory Affairs (as Country or Regional Manager) or Marketing (as Product Manager). Moving backwards from marketing to R&D is much harder though.
- You can move lateral (e.g. switch in the same position from one country to another) or move up (e.g. become a Project Team Manager or Group Product Manager).
- You can start an international career, working in several countries worldwide and then return to the company headquarters for a senior management job.
- You can switch from one company to another within the pharmaceutical industry, or you can switch from a CRO to a pharma company, or you can switch back to academia, or start a career in a governmental agency.
With every career move, you confront new challenges and over the years you get more responsibility, eventually as senior manager. The ultimate move may be that you become Chief Executive Officer (CEO), the ‘big boss’ of a company.
As an alternative career option, you can also start your own company, either as a young entrepreneur or as a senior consultant. Both these options require a solid business plan and an entrepreneurial mindset.
7. Training opportunities
Given the high number of job and career opportunities described above, the main challenge for young students and graduates is to understand which are their preferred jobs and how to get them.
A useful approach is to attend all possible orientation events such as career days, organised nowadays by most universities in which it is possible to listen to experts coming from different companies.
Some of the biggest pharmaceutical companies, including Abbott1
http://www.abbott.com/careers/students/development-programs.html
, AbbVie2
http://www.abbvie.com/careers/student-opportunities/development-programs.html
, Amgen3
http://careers.amgen.com/university-relations/internships-co-ops/
, AstraZeneca4
http://www.astrazenecacareers.com/students/programmes/
, Baxter5
http://www.baxter.com/careers/programs/healthcare-internships-co-ops.page
, Bayer6
https://career.bayer.com/en/career/working-at-bayer/students/
, Biogen7
https://www.biogen-international.com/en/careers1/pharmd-fellowships.html
, Boehringer-Ingelheim8
http://careers.boehringer-ingelheim.com/students
, Bristol-Myers Squibb9
, Eli Lilly & Co10
https://careers.lilly.com/campus
, Gilead11
http://www.gilead.com/careers/careers/current-opportunities
, GlaxoSmithKline12
http://futureleaders.gsk.com/en-gb/our-programmes/
, Johnson & Johnson13
http://www.careers.jnj.com/explore-careers-student
, Merck & Co14
http://www.merck.com/careers/life-at-merck/students-and-graduates.html
, Merck KGaA15
http://www.merckgroup.com/en/careers/graduates_and_students/faq/faq.html
, Novartis16
https://www.novartis.com/careers
, Novo Nordisk 17
, Roche18
http://www.roche.com/careers/switzerland/ch_your_job/students_and_graduates/trainee_programs.htm
, Sanofi19
http://en.sanofi.com/careers/join_sanofi/graduates_interns/graduates_interns.aspx
, Teva20
http://www.tevapharm.com/teva_careers/european_leadership_programme/
have excellent traineeship programmes for young students and graduates.
Useful websites to find excellent scientific positions in public or private institutions are https://www.sciencemag.org/careers, http://www.nature.com/naturejobs/science/, http://jobs.newscientist.com/, etc.
Another valuable strategy is to apply for a traineeship in a company in another European country participating in the Erasmus+ programme.21
https://ec.europa.eu/programmes/erasmus-plus/node_en
The programme offers the possibility of spending periods of at least two months in non-academic institutions including pharmaceutical companies and research centres.22
https://ec.europa.eu/programmes/erasmus-plus/individuals_en#tab-1-4
Most universities are active in this programme and students can easily obtain detailed information from their international offices.
Some European Institutions such as the European Medicines Agency (EMA),23
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000321.jsp
the European Centre for Disease Prevention and Control (ECDC),24
http://ecdc.europa.eu/en/aboutus/jobs/Pages/Traineeships.aspx
and the European Patent Office (EPO)25
http://www.epo.org/about-us/jobs/vacancies/internships.html
offer very interesting traineeships.
The Innovative Medicine Initiative (IMI),26
Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients, has several interesting projects in the field of education and training:
- European Medicines Research Training Network27 http://www.emtrain.eu/ (EMTRAIN), a platform for education and training covering the whole life cycle of medicines research, from basic science through clinical development to pharmacovigilance.
- European programme in Pharmacovigilance and Pharmacoepidemiology28 https://www.eu2p.org/ (Eu2P) which developed numerous courses covering various aspects of medicines’ research and development, including pharmacovigilance.
- Pharmaceutical Medicine Training Programme29 http://www.pharmatrain.eu/ (Pharmatrain), which established standards for high-quality postgraduate education and training in Medicines Development.
- European Modular Education and Training Programme in Safety Sciences for Medicines30 http://www.safescimet.eu/ (SafeSciMET) which established a new and unique pan-European education and training network, providing master’s level courses in safety sciences for medicines.
Another important question often asked by students and graduates is related to the necessary level of education required for the different positions in the pharmaceutical sector. The answer to it is not always easy because despite the harmonization of the architecture of the European higher education obtained through the Bologna process since 199931
http://ec.europa.eu/education/policy/higher-education/bologna-process_en.htm
(1st cycle or bachelor’s degree, 2nd cycle or master’s degree, 3rd cycle or PhD or Doctorate), there are still significant differences in the pharmaceutical field. In most European countries, while chemistry, biology and biotechnology are usually studied in two subsequent cycles (bachelor + master), pharmacy and industrial pharmacy are usually 5 or 6years integrated master’s degree programmes. In addition, in some countries, such as Italy and France for example, it is very common to attend a ‘professional master’ after the master’s degree to obtain the necessary knowledge and skills to be hired by pharma companies for positions in clinical monitoring, pharmacovigilance, or regulatory affairs. Finally, concerning the third cycle, despite the existence of many different research and professional PhDs, it should be mentioned that in most countries, the title of PhD is really necessary for careers in research, but not for most of the other positions described in this chapter.
